Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35703 PUMA BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 77-0683487 (State or other jurisdiction of incorporation or organization) Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTIO ...

Financial Performance - For Q3 2025, Consolidated Edison reported total operating revenues of $4,530 million, a 10.7% increase from $4,092 million in Q3 2024[17]. - Net income for Q3 2025 was $688 million, up 17% from $588 million in Q3 2024, resulting in a diluted net income per share of $1.90[17][18]. - For the nine months ended September 30, 2025, total operating revenues reached $12,924 million, a 11.5% increase compared to $11,587 million for the same period in 2024[17]. - Operating income for the nine months ended September 30, 2025, was $2,448 million, reflecting a 11.6% increase from $2,193 million in 2024[17]. - Net income for the nine months ended September 30, 2025, was $1,606 million, up 13.3% from $1,417 million in the same period of 2024[24]. - Total comprehensive income for Q3 2025 was $639 million, compared to $537 million in Q3 2024[24]. - The company’s comprehensive income for the nine months ended September 30, 2025, was $1,598 million, an increase from $1,417 million in 2024[24]. Operating Expenses and Income - The company’s total operating expenses for Q3 2025 were $3,562 million, a 10.3% increase from $3,230 million in Q3 2024[17]. - Total operating expenses for Q3 2025 were $3,267 million, a 10.4% increase from $2,959 million in Q3 2024[23]. - The total operating income for CECONY for the three months ended September 30, 2025, was $914 million, compared to $803 million in 2024, representing a growth of 13.8%[121]. - The total operating income for the nine months ended September 30, 2025, was $10,476 million, compared to $9,364 million for the same period in 2024, indicating an increase of 11.8%[17]. Cash Flow and Assets - The company reported net cash flows from operating activities of $3,320 million for the nine months ended September 30, 2025, compared to $2,304 million in 2024[19]. - Total assets as of September 30, 2025, were $71,844 million, an increase from $70,562 million at the end of 2024[20]. - The balance of cash and temporary cash investments decreased to $181 million as of September 30, 2025, from $1,324 million at the end of 2024[20]. - Cash flows from operating activities for the nine months ended September 30, 2025, were $3,111 million, an increase from $2,087 million in 2024[25]. - Total current liabilities decreased to $5,079 million as of September 30, 2025, down from $6,433 million at the end of 2024[21]. Shareholder Equity and Dividends - The balance of shareholders' equity increased to $24,168 million as of September 30, 2025, up from $21,962 million at the end of 2024[21]. - The company issued common stock dividends of $0.85 per share, totaling $295 million for the nine months ended September 30, 2025[22]. - The average number of shares outstanding for basic shares increased to 360.7 million in Q3 2025 from 346.2 million in Q3 2024[17]. Debt and Liabilities - Consolidated Edison’s interest expense for the nine months ended September 30, 2025, was $922 million, compared to $883 million in 2024[17]. - Long-term debt increased slightly to $24,909 million as of September 30, 2025, compared to $24,651 million at the end of 2024[21]. - Total current liabilities decreased by 20% from $5,559 million in December 2024 to $4,458 million in September 2025[27]. - CECONY's regulatory liabilities decreased from $5,546 million in December 31, 2024, to $5,069 million as of September 30, 2025[61]. Regulatory and Rate Changes - CECONY's electric base rate changes for the three-year period from January 2026 to December 2028 include increases of $222 million in Year 1, $473 million in Year 2, and $329 million in Year 3[45]. - CECONY's gas base rate changes include a decrease of $46 million in Year 1, followed by increases of $170 million in Year 2 and $93 million in Year 3[47]. - The Joint Proposal for CECONY's electric and gas rate plans is subject to approval by the New York State Public Service Commission[44]. Environmental and Legal Liabilities - The estimated aggregate undiscounted potential liability for the investigation and remediation of environmental contaminants at Con Edison’s manufactured gas plant sites is up to $3,391 million, while for CECONY it is $3,237 million[88]. - Con Edison and CECONY have accrued estimated liabilities for asbestos suits totaling $8 million and $7 million, respectively, as of September 30, 2025, consistent with the previous year[91]. - For the nine months ended September 30, 2025, Con Edison incurred investigation and remediation costs of $12 million, down from $27 million in 2024, while CECONY's costs were $11 million compared to $27 million in the previous year[87]. Tax Expenses - The income tax expense for Con Edison was $202 million for the three months ended September 30, 2025, compared to $133 million in 2024, reflecting an effective tax rate of 22.7%[97]. - CECONY's income tax expense for the same period was $187 million, up from $119 million in 2024, also with an effective tax rate of 22.7%[97]. - The effective tax rate for CECONY increased to 22.4% in 2025 from 17.5% in 2024, indicating a significant rise in tax burden[100]. Capital Expenditures - Capital expenditures for CECONY's electric operations are projected at $4,550 million in Year 1, $4,474 million in Year 2, and $4,712 million in Year 3[45]. - Capital expenditures for gas operations are estimated at $1,093 million in Year 1, $1,057 million in Year 2, and $1,065 million in Year 3[47]. - CECONY plans to implement a low carbon fuels pilot program for steam generation, with an estimated cost of $332 million for four steam decarbonization projects[53].

Financial Performance - Revenues of $76.5 million in Q3 2025, up 4.6% from $73.1 million in Q3 2024[61] - Operating income of $7.6 million in Q3 2025, up 16.5% from $6.5 million in Q3 2024[61] - Net income of $6.1 million in Q3 2025, up 6.3% from $5.7 million in Q3 2024[61] - Adjusted EBITDA of $19.1 million in Q3 2025, up 7.9% from $17.7 million in Q3 2024[61] - Revenues increased by $6.9 million, or 3%, to $224.4 million for the nine months ended September 30, 2025, compared to $217.4 million for the same period in 2024[80] - Subscription revenues rose by $7.5 million, or 4%, to $216.6 million, representing 97% of total revenues for the nine months ended September 30, 2025[81] - Net income for the nine months ended September 30, 2025, was $15.8 million, compared to $15.1 million for the same period in 2024, with EPS increasing to $0.52 from $0.50[88] - Adjusted EBITDA was $52.9 million for the nine months ended September 30, 2025, compared to $50.6 million for the same period in 2024[88] Revenue Composition - Subscription revenues increased by $4.0 million, or 6%, while professional services revenues decreased by $0.6 million, or 19% in Q3 2025 compared to Q3 2024[69] Cost and Expenses - Cost of revenues increased by $2.0 million, or 8%, to $26.5 million in Q3 2025, with cost of revenues as a percentage of revenues rising to 35% from 33%[70] - General and administrative expenses decreased by $1.2 million, or 13%, to $7.3 million in Q3 2025, representing 10% of revenues compared to 12% in Q3 2024[73] - Cost of revenues increased by $5.6 million, or 8%, to $78.4 million, with cost of revenues as a percentage of revenues rising to 35% from 33%[81] Cash Flow and Investments - Net cash provided by operating activities increased by $3.6 million to $50.1 million during the nine months ended September 30, 2025[95] - Net cash used in investing activities was $27.0 million for the nine months ended September 30, 2025, compared to $25.9 million for the same period in 2024[96] - Capital expenditures were $7.5 million in Q3 2025, compared to $6.8 million in Q3 2024, reflecting increased investment in product development[66] Shareholder Returns - The company repurchased 905,786 shares of common stock at an aggregate fair value of $25.0 million during the nine months ended September 30, 2025[103] Financial Position - The company has a working capital of $35.1 million as of September 30, 2025, down from $37.4 million at December 31, 2024[98] - The company has a $50.0 million revolving credit facility with no outstanding borrowings as of September 30, 2025[99] - The Company is in compliance with all covenants under its revolving credit facility as of September 30, 2025[105] - The Company had no outstanding debt as of September 30, 2025, but may face interest rate market risk with future borrowings[107] Cash and Investment Risks - Cash and investment balances were $92.6 million as of September 30, 2025, with a hypothetical 10% decrease in interest rates potentially reducing annual interest income by $0.3 million[107] - The Company is exposed to foreign currency risks related to revenues and operating expenses in currencies such as the Canadian dollar, New Zealand dollar, and Australian dollar[108] - The Company has not entered into foreign currency hedging contracts to date but may consider doing so in the future[109] - The Company's investment strategy focuses on highly rated securities to minimize principal loss risk, with limits on credit exposure to single issuers[110] - The investment portfolio includes strategic investments in early-stage healthcare technology companies to expand the ecosystem[111] - The Company may experience volatility in its financial statements due to changes in market prices and impairments of strategic investments[111] - Future results may differ materially from projected market risks due to actual market developments[112] Taxation - The effective tax rate was 26% for Q3 2025, compared to 23% for Q3 2024[76] - The company expects to record sublease income of approximately $0.8 million during the last three months of 2025 and $3.2 million annually thereafter[62]

Financial Performance - Revenue for Q3 2025 increased by 17.0% to $572.8 million, compared to $489.6 million in Q3 2024[4] - Net income for Q3 2025 was $49.8 million, an increase of 8.9% from $45.8 million in Q3 2024[5] - Adjusted EBITDA rose by 17.1% to $118.9 million in Q3 2025, up from $101.6 million in Q3 2024[5] - Revenue for the nine months ended September 30, 2025, was $1,624,337, representing a 13.2% increase from $1,435,151 in 2024[25] - Net income for the nine months ended September 30, 2025, was $136,658, a decrease of 8.8% from $149,097 in 2024[34] - Basic and diluted earnings per share for the nine months ended September 30, 2025, was $1.03, compared to $1.32 in 2024[28] - Net income for Q3 2025 was $49,822, representing 8.7% of revenue, compared to $45,759 (9.3%) in Q3 2024[44] - Adjusted net income attributable to the company for Q3 2025 was $49,929, or $0.39 per share, compared to $44,306 ($0.37) in Q3 2024[49] Operational Metrics - Patient visits totaled 3,557,697 in Q3 2025, averaging 55,589 visits per day, a 9.2% increase from Q3 2024[5] - Total patient visits for the nine months ended September 30, 2025, were 10,282,385, a 6.8% increase compared to 9,628,515 in 2024[38] - The number of occupational health centers increased to 628 by the end of September 2025, up from 549 in 2024, with 72 centers acquired during the period[38] - The company operated 413 onsite health clinics by the end of September 2025, compared to 156 in 2024[38] - Revenue per visit for workers' compensation increased by 4.7% to $211.82 in Q3 2025 from $202.29 in Q3 2024[36] Financial Position - The company reported a cash balance of $49.9 million and reduced net leverage to 3.6x as of September 30, 2025[8] - Total assets increased to $2,843,930 as of September 30, 2025, from $2,521,164 at the end of 2024[32] - Cash at the end of the period decreased to $49,941 from $183,255 at the beginning of the period[32] - Current liabilities increased slightly to $312,650 as of September 30, 2025, compared to $307,186 at the end of 2024[32] Expenses and Costs - Total costs and expenses rose by 14.3% to $1,360,024 for the nine months ended September 30, 2025, from $1,189,759 in 2024[25] - Interest expense surged by 287.4% to $82,424 in 2025, compared to $21,275 in 2024[25] - Interest expense for Q3 2025 was $28,683, which is 5.0% of revenue, compared to $21,369 (4.4%) in Q3 2024[44] - Cash paid for interest increased significantly to $94,135 in 2025 from $34,221 in 2024[34] Guidance and Future Expectations - Concentra raised its full-year 2025 revenue guidance to a range of $2.145 billion to $2.160 billion[17] - The company expects full-year 2025 adjusted EBITDA to be in the range of $425 million to $430 million[54] - The anticipated net income attributable to the company for 2025 is projected between $156 million and $161 million[54] Shareholder Actions - A cash dividend of $0.0625 per share was declared, payable on December 9, 2025[10] - The company authorized a share repurchase program of up to $100 million, set to expire on December 31, 2027[12] Capital Expenditures - Capital expenditures for 2025 are expected to be in the range of $80 million to $90 million[17] Other Financial Activities - The company reported a loss on early retirement of debt amounting to $875 in 2025, with no such loss reported in 2024[25] - The company reported a net cash used in investing activities of $394,725 for the nine months ended September 30, 2025, compared to $54,579 in 2024[34] - Separation transaction costs for Q3 2025 were $1,025, representing 0.2% of revenue[44] - The company incurred $1,181 in acquisition costs related to Nova and Pivot Onsite Innovations in Q3 2025[44]

Exhibit 99.1 MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended September 30, 2025 Results for the Quarter Ended September 30, 2025 and Other Recent Highlights: 1 • Net investment income per share for the quarter was $0.38, compared to $0.39 for the quarter ended June 30, 2025 • Net asset value per share as of the end of the quarter was $14.66, compared to $14.75 as of June 30, 2025, a decrease of 0.6% • New investment commitments made during the quarter totaled $138 mil ...

Exhibit 99.1 MidCap Financial Investment Corporation Reports Financial Results for the Quarter Ended September 30, 2025 Results for the Quarter Ended September 30, 2025 and Other Recent Highlights: 1 • Net investment income per share for the quarter was $0.38, compared to $0.39 for the quarter ended June 30, 2025 • Net asset value per share as of the end of the quarter was $14.66, compared to $14.75 as of June 30, 2025, a decrease of 0.6% • New investment commitments made during the quarter totaled $138 mil ...

Operations and Facilities - As of September 30, 2025, the company operates or manages 80 skilled nursing facilities with a total of 10,329 licensed beds, 26 assisted living facilities with 1,413 units, and 34 homecare agencies[143]. - The overall occupancy rate in owned and leased skilled nursing facilities was 90.0% for the three months ending September 30, 2025, compared to 88.3% for the same period a year ago[144]. - The company has 47 skilled nursing facilities rated 4 or 5 stars, representing 59% of its total facilities, compared to 37% in the industry[148]. - The average census at skilled nursing facilities increased to 90.0% from 88.3% year-over-year[176]. - The average census at skilled nursing facilities increased to 89.6% for the nine months ended September 30, 2025, compared to 88.6% for the same period in 2024[188]. Financial Performance - For the three months ended September 30, 2025, net operating revenues increased by 12.5% to $382,661,000 compared to $340,198,000 for the same period in 2024[173]. - Net patient revenues rose by $42,315,000, or 12.9%, to $370,989,000 compared to $328,674,000 for the same quarter last year[175]. - Adjusted net income for the quarter was $24,744,000, reflecting a 24.3% increase from $19,910,000 in the same period of 2024[174]. - Net operating revenues increased by 20.6% for the nine months ended September 30, 2025, driven by a 9.2% increase in same-facility net operating revenues and the acquisition of White Oak[185]. - GAAP net income attributable to the company for the nine months ended September 30, 2025, was $95,166,000, a decrease from $95,846,000 in 2024, while adjusted net income increased by 47.9% to $75,293,000[186]. - Net patient revenues increased by $201,530,000, or 22.5%, compared to the same period last year[187]. Costs and Expenses - The total costs and expenses increased by $34,874,000, or 11.0%, to $352,283,000 from $317,409,000 in the prior year[178]. - Other operating expenses increased by $14,095,000, or 17.1%, to $96,604,000 for the three months ended September 30, 2025, compared to $82,509,000 for the same period in 2024[181]. - Total costs and expenses increased by $158,985,000, or 18.1%, to $1,036,033,000 for the nine months ended September 30, 2025[190]. - Salaries, wages, and benefits increased by $19,781,000, or 9.3%, to $233,176,000, with a percentage of net operating revenues decreasing to 60.9% from 62.7%[179]. - Salaries, wages, and benefits increased by $111,231,000, or 19.3%, to $687,840,000, with salaries as a percentage of net operating revenues decreasing to 60.8%[191]. Medicaid and Medicare Rates - The average Medicare per diem rate for skilled nursing facilities increased by 5.9% for the first nine months of 2025 compared to the same period in 2024[155]. - The fiscal year 2026 Medicare payment rates for skilled nursing facilities include a net increase of 3.2% compared to 2025 levels[153]. - The state of Tennessee's Medicaid increase is estimated to generate an additional $3,000,000 annually, or $750,000 per quarter, starting from fiscal year 2026[156]. - The state of South Carolina's Medicaid increase is estimated to generate an additional $4,200,000 annually, or $1,050,000 per quarter, starting from fiscal year 2026[157]. - Medicare per diem rates increased by 6.1%, while managed care per diem rates decreased by 7.1% compared to the same quarter last year[176]. Acquisitions and Partnerships - The company purchased the assets of White Oak Management, which included 15 skilled nursing facilities and 1,928 licensed skilled nursing beds[150]. - The White Oak operations contributed an increase of $20,026,000 in net patient revenues for the quarter ended September 30, 2025[177]. - The company is focusing on partnerships with hospital systems and payors to enhance its position in post-acute healthcare services[146]. Cash Flow and Liquidity - Cash provided by operating activities for the nine months ended September 30, 2025, was $168,271,000, an increase of 78.0% compared to $94,514,000 in the same period last year[201]. - Net cash used in investing activities was $20,924,000 for the nine months ended September 30, 2025, significantly lower than $225,048,000 for the same period in 2024[203]. - Net cash used in financing activities for the nine months ended September 30, 2025, was $92,735,000, a decrease from cash provided of $119,640,000 for the same period in 2024[205]. - Current cash on hand is $130,629,000, with unrestricted marketable equity securities valued at $166,754,000[207]. - The company has a borrowing capacity of $50 million on its available line of credit, which is expected to support both short-term and long-term liquidity requirements[208]. Marketable Securities - At September 30, 2025, the fair value of marketable equity securities was approximately $184,236,000, with $129.6 million (70.4%) invested in NHI[217]. - The company has net unrealized gains of $141.3 million in its equity securities, with $104.9 million related to the investment in NHI[217]. - The company has available for sale marketable debt securities amounting to $122,912,000 as of September 30, 2025[212]. - A hypothetical 10% change in quoted market prices would result in a related increase or decrease in the fair value of equity investments of approximately $18.4 million[217]. Workforce and Labor - The company faced workforce and labor shortages but is actively working to reduce agency nurse staffing expenses, which decreased to $1,207,000 from $3,099,000 year-over-year[179].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 1-13677 MID PENN BANCORP, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Inc ...

Financial Performance - Total revenues for Q3 2025 were $536.99 million, a decrease of 8.8% from $589.13 million in Q3 2024[16] - Gross profit for Q3 2025 was $200.88 million, compared to $204.85 million in Q3 2024, reflecting a gross margin of approximately 37.3%[16] - Net loss for Q3 2025 was $3.40 million, or $0.14 per share, compared to a net loss of $32.98 million, or $1.35 per share, in Q3 2024[16] - Total revenues for the three months ended September 30, 2025, were $536,990, a decrease of 8.8% compared to $589,131 for the same period in 2024[63] - For the nine months ended September 30, 2025, total revenues were $1,690,558, down from $1,752,241 in 2024, reflecting a decline of 3.5%[63] - The company reported a net gain on the sale of business amounting to $44,792 thousand in the nine months ended September 30, 2025[25] - The company recognized a consolidated net loss of $3,396 for the three months ended September 30, 2025, compared to a loss of $32,983 in 2024[74] - For the nine months ended September 30, 2025, the net income was $16.466 million, a significant improvement from a net loss of $93.860 million in the same period of 2024[86] Assets and Liabilities - Total current assets decreased to $1.21 billion as of September 30, 2025, from $1.44 billion at December 31, 2024[14] - Total liabilities decreased to $1.93 billion as of September 30, 2025, from $2.20 billion at December 31, 2024[14] - Total assets as of September 30, 2025, were $4.10 billion, a decrease from $4.20 billion at December 31, 2024[14] - The company’s total contract liabilities decreased to $37,213 as of September 30, 2025, from $42,177 at the beginning of the year[65] - The company’s accrued liabilities totaled $316,103 thousand as of September 30, 2025, compared to $306,923 thousand as of December 31, 2024, reflecting an increase of about 3.9%[121] Expenses - Operating expenses for Q3 2025 were $187.16 million, down from $196.62 million in Q3 2024, indicating a reduction of approximately 4.5%[16] - Research and development expenses remained stable at $21.25 million in Q3 2025, compared to $21.03 million in Q3 2024[16] - Depreciation and amortization for the nine months ended September 30, 2025, was $149,912 thousand, down from $166,519 thousand in 2024[25] - Stock compensation expense for the nine months ended September 30, 2025, was $41,879 thousand, compared to $34,366 thousand in 2024[25] - Restructuring expenses for the three and nine months ended September 30, 2025, were $6.2 million and $21.2 million, respectively, compared to $3.6 million and $16.6 million for the same periods in 2024[38] - Strategic transaction and integration expenses for the three and nine months ended September 30, 2025, were $6.9 million and $24.9 million, respectively, down from $13.2 million and $33.5 million in 2024[40] Cash Flow - Cash provided by operating activities for the nine months ended September 30, 2025, was $119,248 thousand, compared to $163,841 thousand in 2024[25] - Net cash used in investing activities for the nine months ended September 30, 2025, was $140,620 thousand, while it was $(62,414) thousand in 2024[25] - Cash and cash equivalents at the end of the period on September 30, 2025, were $299,732 thousand, down from $312,512 thousand at the end of September 30, 2024[25] Debt and Financing - Principal repayments of long-term debt for the nine months ended September 30, 2025, totaled $272,750 thousand, compared to $38,250 thousand in 2024[25] - The company made a prepayment of $200 million on Term Loan A during the second quarter of 2025, funded by the sale of its IV Solutions business[143] - The outstanding principal balance of Term Loan A was $559.7 million as of September 30, 2025, with no borrowings under the $500 million revolving credit facility[173] - The company was in compliance with all financial covenants as of September 30, 2025[151] - The maximum Senior Secured Leverage Ratio is 4.50 to 1.00 until June 30, 2024, and thereafter it will be 4.00 to 1.00[149] Investments and Acquisitions - The company recognized a gain of $44.8 million from the sale of a 60% ownership interest in its IV Solutions business, which included a $45.6 million gain from the disposal and a $19.4 million gain from the fair value of the retained 40% interest[48] - The investment in Otsuka ICU Medical LLC was recorded at $131.1 million as of September 30, 2025, reflecting the retained 40% interest in the IV Solutions business[108] - The total consideration for the acquisition of Smiths Medical included a potential earn-out payment of $100 million contingent on stock price targets[96] Taxation - The effective tax rate for the three months ended September 30, 2025, was 26%, compared to an effective tax rate of (84)% for the same period in 2024[120] - The company recorded a tax benefit of $12.0 million for the year ended December 31, 2024, related to U.S. return-to-provision adjustments[123] - The company has considered the impact of the EU's Pillar Two legislation on its tax provision for fiscal year 2025, which may alter tax obligations in certain countries[124] Other Financial Metrics - The company’s total comprehensive loss for the nine months ended September 30, 2025, was $105,395 thousand[22] - The company recorded a net reversal of $0.7 million for the estimated costs related to field service corrective actions associated with the 2021 FDA Warning Letter, adjusting the total accrued amount to approximately $23.3 million[163] - The company has a share purchase plan approved for up to $100 million, with no shares purchased under this plan during the three months ended September 30, 2025[156]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-22891 ...